We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.

Atlas Venture

OrbiMed

T. Rowe Price

Cystic Fibrosis Foundation

The Rise Fund

TPG Rise Climate Fund

RA Capital Management

Sionna Therapeutics

Managing a cystic fibrosis (#CF) diagnosis can be challenging. Jennifer, whose child is living with CF, has found ways to make the diagnosis less overwhelming. Read about her journey here: https://lnkd.in/dExcKR4g

At Sionna, we exercise our Core Values through our quarterly Culture Blasts. These events provide a way for us to come together regularly, learn about ourselves, practice our leadership skills and celebrate our achievements! 

During our most recent #CultureBlast in March, we had a great time celebrating our successful Series C financing and engaging in team bonding activities. Check out some pictures from the event!  

Just a few weeks after closing our Series C round, President & CEO Michael Cloonan reflected on the process of a private funding round and the key drivers of success including science, relationships and experience.  
 
Find the full post on the "From The Trenches" LifeSciVC blog organized by Bruce Booth of Atlas Venture: https://lnkd.in/es4mmfCz

We take calculated risks and purposefully explore creative ways to raise the bar for people living with cystic fibrosis (CF). In line with our core value of Intentional Innovation, Juliet Labadorf, Senior Director, Financial Planning & Analysis, shares a message about Sionna’s dynamic approach to CF therapeutic development.  

We are committed to the collective well-being of our entire team. That’s why we value flexibility, prioritize employee-driven ways of working, and offer policies designed to enhance work/life balance. 

Learn more about life at Sionna: https://lnkd.in/etdzEAVY 

A biotechnology company focused on developing therapies to fully normalize CFTR function, targeting the NBD1, ICL4, and TMD1 regions of CFTR to achieve best-in-class efficacy for patients with cystic fibrosis.

COM:SIONNATX

Sionna Therapeutics

Filings Not Available